Novel Antipsychotics: Ulotaront (TAAR1 Agonis...

Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry.References:Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfd ...  Show more

Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry. References: https://www.ncbi.nlm.nih.gov/books/NBK534811/https://pubmed.ncbi.nlm.nih.gov/24825644/https://pubmed.ncbi.nlm.nih.gov/26798982/https://www.nejm.org/doi/full/10.1056/NEJMct08017 ...  Show more

In the third episode of our “Art of Psychiatry” series, we will discuss schizophrenia, a chronic mental illness that affects 1% of the population. We will focus especially on the patient experience of what it’s like to live with schizophrenia. We’ll start by reviewing the key sym ...  Show more

Contributors: Andrew White MD & Travis Barlock MD

In this follow-up episode Dr. Andrew White, a practicing psychiatrist with an addiction medicine fellowship, and Dr. Travis Barlock, an emergency physician at Swedish Medical Center, ...

In this episode, we are joined by a panel of experts to discuss treatment of psychosis. Experiences of psychosis are common. When these experiences lead to interference in achieving life goals and/or distress, individuals can benefit from seeking evidenced-based care. The earlier ...  Show more

Dr Matthew Broome discusses what is known about predicting the risk of transition to psychosis in high risk groups Senior Clinical Research Fellow Matthew Broome discusses what is known about predicting future psychotic conditions such as schizophrenia or bipolar. He discusses th ...  Show more